SainuoSheng Plans Hong Kong Main Board Listing with Gene Therapy Platform
Shenzhen-based SainuoSheng is planning a Hong Kong main board IPO, supported by stable Gendicine revenues and its virus-vector gene therapy ...
Read more
Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.
📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com